Foe to Ally: Oncolytic Virus-Driven Xenorejection Ignites Potent Antitumor Immunity

Yanglin Xu; Bingcheng Chang; Wei He; Jia Liu

doi:10.1002/mog2.70025

MEDCOMM - Oncology ›› 2025, Vol. 4 ›› Issue (2) :e70025 DOI: 10.1002/mog2.70025

HIGHLIGHT

Foe to Ally: Oncolytic Virus-Driven Xenorejection Ignites Potent Antitumor Immunity

Author information +

History +

PDF

Cite this article

Download citation ▾

Yanglin Xu, Bingcheng Chang, Wei He, Jia Liu. Foe to Ally: Oncolytic Virus-Driven Xenorejection Ignites Potent Antitumor Immunity. MEDCOMM - Oncology, 2025, 4(2): e70025 DOI:10.1002/mog2.70025

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	L. Zhong, L. Gan, B. Wang, et al., “Hyperacute Rejection-Engineered Oncolytic Virus for Interventional Clinical Trial in Refractory Cancer Patients,” Cell 188, no. 4 (2025): 1119–1136.e23.

[2]	R. Ma, Z. Li, E. A. Chiocca, M. A. Caligiuri, and J. Yu, “The Emerging Field of Oncolytic Virus-Based Cancer Immunotherapy,” Trends in Cancer 9, no. 2 (2023): 122–139.

[3]	P. K. Bommareddy, M. Shettigar, and H. L. Kaufman, “Integrating Oncolytic Viruses in Combination Cancer Immunotherapy,” Nature Reviews Immunology 18, no. 8 (2018): 498–513.

[4]	D. Lin, Y. Shen, and T. Liang, “Oncolytic Virotherapy: Basic Principles, Recent Advances and Future Directions,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 156.

[5]	Y. G. Yang and M. Sykes, “Xenotransplantation: Current Status and a Perspective on the Future,” Nature Reviews Immunology 7, no. 7 (2007): 519–531.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm – Oncology published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).